Phase 4 N=119 TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=179 Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
Encephalitis, Tick-Borne
Primary: Seropositivity Rate Measured by Neutralization Test (NT) at 21-35 Days After the First Tick-borne Encephalitis (TBE) Booster Vaccination in Study 700401 — 100.0…
Phase 4 N=205 Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
Tick Borne Encephalitis · Virus Diseases
Primary: Percentage of Subjects With Detectable TBE Antibody Titers Greater Than or Equal to (≥) 2 — 95.83; 100.0; 97.17 Percentage of subjects
Phase 3 N=165 Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
Tick-Borne Encephalitis
Primary: Percentage of Seropositive Participants at 4 Weeks After Dose 3 — 98.0; 100 Percentage of participants
Phase 2 N=34 Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Tick Borne Encephalitis
Primary: Outcome of the Neutralization Test (Number of Subjects With Antibody Response Measured by Neutralization Assay) — 6; 14 Participants — p=<0.001
Phase 3 N=302 Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
Encephalitis, Tick-Borne
Primary: Seropositivity Rate as Determined by Neutralization Test (NT) 28 Days After the Second Vaccination — 100; 97.8 Percentage of participants — p=<0.001
N/A N=159 Tick-borne Illness and Clothing Study
Tick Bites · Tick-borne Illness
Primary: Work Related Tick Bites — 265; 780 tick bites — p=0.004
Phase 4 N=194 The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
Virus Diseases
Primary: Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 11 — 100; 100; 99.0 Percentage of participants
N/A N=71 Xenodiagnosis After Antibiotic Treatment for Lyme Disease
Lyme Disease
Primary: Detection of Borrelia Burgdorferi in Ticks After Xenodiagnosis Procedure — 1; 0; 418; 319 Ticks
Phase 4 N=305 Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine
Japanese Encephalitis
Primary: Percentage of Participants With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 98.0; 99.3; 100.0; 100.0 percentage of participants
Phase 3 N=152 Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children
Encephalitis, Japanese B
Primary: Seroconversion Rate After Primary Vaccination — 100 percentage of seroconversion
Phase 1 N=30 VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
N/A N=3,258 Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT) — 81.8 percentage of subjects
Phase 4 N=17 A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2
Japanese Encephalitis · Japanese Encephalitis Vaccine
Primary: Change of T Lymphocyte Responses to Live Attenuated JE SA-14-14-2 Vaccine at Week 2. — 34 IFNγ SFC/million PBMC
Phase 3 N=2,675 Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: Safety and Tolerability up to Day 56 — 58.9; 56.6 percentage of participants with AEs
Phase 3 N=349 Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: Long Term Immunogenicity of IC51 Vaccine 24 Months After the Primary Vaccination — 56; 7; 5 percentage of participants
Phase 3 N=596 Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers
Encephalitis · Japanese Encephalitis
Primary: Percentage of Participants With Japanese Encephalitis Seroprotection Following a Single Dose of JE-CV — 2.6; 100.0; 88.2; 90.0 Percentage of participants
Phase 2 N=138 Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine
Eastern Equine Encephalitis
Primary: Subject Response Rates for PRNT80 Titers — 39; 28; 48; 79 Participants
N/A N=22 Transcranial Magnetic Stimulation for BECTS
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04
Phase 3 N=1,869 Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population
Encephalitis
Primary: Rate of Subjects With Serious Adverse Events and Medically Attended Adverse Events Until Day 56 After First Vaccination — 16.1; 14.2; 38.2; 42.2 percentage of…
Phase 3 N=121 Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis
Neuroborreliosis, Borrelia Burgdorferi
Primary: Difference in Composite Clinical Score From Inclusion to Six Months After Ended Treatment — 6.4; 6.4 units on a scale
Phase 3 N=374 Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: SCR (Seroconversion Rate) at Day 56 — 41.2; 97.3; 25.6 percentage of participants — p=>0.99
Phase 3 N=639 Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: GMT for Anti-JEV Neutralizing Antibody — 160.71; 272.24; 127.56 GMT
N/A N=3,570 A School-Based Intervention to Reduce Lyme Disease
Lyme Disease
Primary: The Incidence of Lyme Disease Among Children and Families Living in an Endemic Area Using an Educational Intervention — 1; 1 Number of cases incident Lyme disease
N/A N=4,461 Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
Aedes-borne Diseases · Dengue · Chikungunya
Primary: Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically — 213; 209; 151; 146 Participants
Phase 3 N=300 Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
Japanese Encephalitis
Primary: SCRs (Seroconversion Rate) as Defined by Percentage of Subjects With Plaque Reduction Neutralization Test Titers of>1:10 at 1 Month After the Booster Dose — 100; 100…
Phase 4 N=278 Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age
Japanese Encephalitis
Primary: Number and Percentage of Subjects With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 14; 243; 233; 24 Participants
Phase 3 N=867 Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56 — 96.4; 93.6 percentage of participants
Phase 3 N=542 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
Japanese Encephalitis · Measles · Mumps
Primary: Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or…
Phase 3 N=304 Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
Japanese Encephalitis
Primary: Primary: 1. Geometric Mean Titers (GMT) at Day 56 — 100.1; 84.7; 68.1 Geometric Mean Titer - Estimate